



Anti-Tau [pS422] Mouse Monoclonal Antibody (clone 2H9)

Ref. 4BDX-1501

Biomolecule

Anti-Tau [pS422] Mouse monoclonal antibody

Clone

2H9

Size

 $100 \mu g / 100 \mu L$

Formulation

Solution in PBS at 1 mg/mL

Storage

+4°C / -20°C

Immunogen

Peptide

Specificity

Anti-Tau phosphorylated at serine 422

Cross-reactivity

Human, Mouse, Rat

Immunoglobulin type

Human Tau specific mouse IgG

Isotype

IgG2a Kappa

Applications

Western-blot, Immunohistochemistry, Immunofluorescence, Immunotherapy

Preparation

This antibody was produced from a mouse hybridoma resulting from a mouse immunized with a peptide covering the human Tau protein sequence with the phospho-serine 422.

• **Purity**

Mouse monoclonal antibodies 2H9 was purified by protein A/G affinity chromatography. Purity > 90%, as determined by SDS-PAGE and visualized by Coomassie blue staining.

Concentration

The measured concentration of the purified Anti-Tau [pS422] was 1 mg/ml as determined using a total protein concentration assay.

• Specificity

Determined by its ability to recognise human Tau phosphorylated at serine 422.

Storage

Store at +4°C for short term use (1-2 weeks) - Store at -20°C for long term use.

• Applications

Recommended concentration of use are:

Western-blot: 0.2 µg/mL

IHC/IF: 2 μg/mL

For Research Use Only V1_0118






Tau proteins are encoded by a single gene MAPT (Gene ID:4137). They belong to the family of microtubule-associated proteins. The phosphorylation of Tau protein at serine 422 is a pathological epitope and a marker of neurofibrillary degeneration, one of the neuropathological hallmark of Alzheimer's disease. On cerebral tissue, 2H9 Tau antibody detects neurons in neurofibrillary degeneration. The serine 422 is phosphorylated by the following kinases: CaMKII (Calcium Calmodulin-kinase II), PKA (protein kinase A), JNKs (c-Jun N-terminal kinases), ERK1/2 or p42/44 MAKP (mitogen-activated kinases), p38 MAPK and MARK (Microtubule-associated protein/microtubule affinity-regulating kinase).

References


Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D and Buee L (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 9(4):397-405.

Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, and Buée L (2008) Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert review of proteomics 5:207–224.


Application exemples



Western-blotting of human brain tissue (1 control and 2 Alzheimer)



Immunohistochemistry of Thy-Tau22 transgenic model of neurofibrillary degeneration



Immunofluorescence of Thy-Tau22 transgenic model of neurofibrillary degeneration

TO PLACE AN ORDER



For Research Use Only V1_0118